These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28406934)

  • 41.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers.
    Gersel Stokholm M; Garrido A; Tolosa E; Serradell M; Iranzo A; Østergaard K; Borghammer P; Møller A; Parbo P; Stær K; Brooks DJ; Martí MJ; Pavese N
    J Neurol; 2020 Aug; 267(8):2296-2300. PubMed ID: 32318850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.
    Helmich RC; Thaler A; van Nuenen BF; Gurevich T; Mirelman A; Marder KS; Bressman S; Orr-Urtreger A; Giladi N; Bloem BR; Toni I;
    Neurology; 2015 Jan; 84(4):399-406. PubMed ID: 25540317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
    Zhang D; Zhou L; Shi Y; Liu J; Wei H; Tong Q; He H; Wu T
    Mov Disord; 2023 Jan; 38(1):138-142. PubMed ID: 36253640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LRRK2 G2019S Parkinson's disease with more benign phenotype than idiopathic.
    Ben Romdhan S; Farhat N; Nasri A; Lesage S; Hdiji O; Ben Djebara M; Landoulsi Z; Stevanin G; Brice A; Damak M; Gouider R; Mhiri C
    Acta Neurol Scand; 2018 Nov; 138(5):425-431. PubMed ID: 29989150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
    Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
    Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arm swing as a potential new prodromal marker of Parkinson's disease.
    Mirelman A; Bernad-Elazari H; Thaler A; Giladi-Yacobi E; Gurevich T; Gana-Weisz M; Saunders-Pullman R; Raymond D; Doan N; Bressman SB; Marder KS; Alcalay RN; Rao AK; Berg D; Brockmann K; Aasly J; Waro BJ; Tolosa E; Vilas D; Pont-Sunyer C; Orr-Urtreger A; Hausdorff JM; Giladi N
    Mov Disord; 2016 Oct; 31(10):1527-1534. PubMed ID: 27430880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
    Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
    Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A
    J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Features of LRRK2 Carriers with Parkinson's Disease.
    Kestenbaum M; Alcalay RN
    Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
    Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.